GlassScriptPhysician profile
Katherine Collins Hoey
NPI 1699092759
$2,554.68
in general payments reported to CMS, 2019-2025
25 companies · $767 in 2025
The $767 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $156 · 2021: $349 · 2022: $174 · 2023: $321 · 2024: $618 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,706.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $589.62 | 2022-2025 | Azstarys |
| Tris Pharma INC | $300.58 | 2019-2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $263.52 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $243.01 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $200.58 | 2019-2025 | Elaprase |
| Adlon Therapeutics L.P. | $167.90 | 2020-2021 | |
| Glaxosmithkline, LLC. | $136.59 | 2019-2025 | Bexsero, Pediarix |
| Merck Sharp & Dohme LLC | $128.55 | 2019-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Neos Therapeutics, LP | $77.77 | 2022 | |
| Sanofi-Aventis U.S. LLC | $56.06 | 2024-2025 | |
| Cranial Technologies, INC | $44.69 | 2020-2025 | Doc Band |
| Supernus Pharmaceuticals, INC. | $40.61 | 2021 | |
| Seqirus USA INC | $38.87 | 2024 | Flucelvax |
| Ars Pharmaceuticals Operations, INC. | $34.33 | 2025 | Neffy |
| Pfizer INC. | $33.54 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $27.80 | 2020-2023 | Strensiq |
| Sobi, INC | $26.19 | 2022 | |
| Avion Pharmaceuticals | $23.77 | 2023 | Methylphenidate Hydrochloride |
| Novartis Pharmaceuticals Corporation | $22.81 | 2019 | |
| Biomarin Pharmaceutical INC. | $21.12 | 2025 | Voxzogo 1.2mg |
| Vertical Pharmaceuticals, LLC | $17.32 | 2024 | Relexxii |
| Cipher Pharmaceuticals US LLC | $15.81 | 2025 | Natroba, Spinosad |
| Abbvie INC. | $15.75 | 2021 | |
| Genentech USA, INC. | $14.24 | 2020 | |
| Kaleo, INC. | $13.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Hoey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.